Antitumoral activity of rapamycin mediated through inhibition of HIF-1alpha and VEGF in hepatocellular carcinoma

Digestive Diseases and Sciences

Volumn 54, Issue 10, 2009, Pages 2128-2136

  Wang, Wei ^a   Jia, Wei Dong ^a   Xu, Ge Liang ^a   Wang, Zhi Hua ^a   Li, Jian Sheng ^a   Ma, Jin Liang ^a   Ge, Yong Sheng ^a   Xie, Sheng Xue ^a   Yu, Ji Hai ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Hepatocellular carcinoma; HIF 1alpha; Rapamycin; VEGF

Indexed keywords

CYCLOSPORIN A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; RAPAMYCIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG METASTASIS; MALE; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS, EXPERIMENTAL; MALE; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SIROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70149089204     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-008-0605-3     Document Type: Article

References (26)

1. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108
2. MC Yu JM Yuan 2004 Environmental factors and risk for hepatocellular carcinoma Gastroenterology 127 S72 S78 10.1016/j.gastro.2004.09.018 (Pubitemid 39423372)
3. Z Wang J Zhou J Fan SJ Qiu Y Yu XW Huang ZY Tang 2008 Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma Clin Cancer Res 14 5124 5130 10.1158/1078-0432.CCR-07- 4774
4. H Huynh PK Chow N Palanisamy M Salto-Tellez BC Goh CK Lee A Somani HS Lee R Kalpana K Yu PH Tan J Wu R Soong MH Lee H Hor KC Soo HC Toh P Tan 2008 Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma J Hepatol 49 52 60 10.1016/j.jhep.2008.02.022
5. DA Guertin DM Sabatini 2007 Defining the role of mTOR in cancer Cancer Cell 12 9 22 10.1016/j.ccr.2007.05.008 (Pubitemid 47001784)
6. S Vignot S Faivre D Aguirre E Raymond 2005 mTOR-targeted therapy of cancer with rapamycin derivatives Ann Oncol 16 525 537 10.1093/annonc/mdi113 (Pubitemid 40613318)
7. X Bu C Le F Jia X Guo L Zhang B Zhang M Wu L Wei 2008 Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells Cancer Biol Ther 7 392 396
8. D Semela AC Piguet M Kolev K Schmitter R Hlushchuk V Djonov C Stoupis JF Dufour 2007 Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma J Hepatol 46 840 848 10.1016/j.jhep.2006. 11.021 (Pubitemid 46529039)
9. M Guba P von Breitenbuch M Steinbauer G Koehl S Flegel M Hornung CJ Bruns C Zuelke S Farkas M Anthuber KW Jauch EK Geissler 2002 Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor Nat Med 8 128 135 10.1038/nm0202-128 (Pubitemid 34155123)
10. A Basu AG Contreras D Datta E Flynn L Zeng HT Cohen DM Briscoe S Pal 2008 Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer Cancer Res 68 5689 5698 10.1158/0008-5472.CAN-07- 6603
11. Z von Marschall T Cramer 2001 Höcker M, Finkenzeller G, Wiedenmann B, Rosewicz S: Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma Gut 48 87 96 10.1136/gut.48.1.87 (Pubitemid 32042647)
12. TK Lee RT Poon AP Yuen MT Ling XH Wang YC Wong XY Guan K Man ZY Tang ST Fan 2006 Regulation of angiogenesis by Id-1 through hypoxia-inducible factor-1alpha-mediated vascular endothelial growth factor up-regulation in hepatocellular carcinoma Clin Cancer Res 12 6910 6919 10.1158/1078-0432.CCR-06- 0489 (Pubitemid 44974483)
13. H Yoshino M Futakuchi YM Cho K Ogawa F Takeshita N Imai S Tamano T Shirai 2005 Modification of an in vivo lung metastasis model of hepatocellular carcinoma by low dose N-nitrosomorpholine and diethylnitrosamine Clin Exp Metastasis 22 441 447 10.1007/s10585-005-2807-9 (Pubitemid 41609303)
14. N Weidner JP Semple WR Welch J Folkman 1991 Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma N Engl J Med 324 1 8
15. MA Zimmerman JF Trotter M Wachs T Bak J Campsen A Skibba I Kam 2008 Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma Liver Transpl 14 633 638 10.1002/lt.21420 (Pubitemid 351696274)
16. Y Mizukami Y Kohgo DC Chung 2007 Hypoxia Inducible Factor-1 Independent Pathways in Tumor Angiogenesis Clin Cancer Res 13 5670 5674 10.1158/1078-0432. CCR-07-0111 (Pubitemid 47583891)
17. Y Mizukami K Fujiki EM Duerr M Gala WS Jo X Zhang DC Chung 2006 Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc J Biol Chem 281 13957 13963 10.1074/jbc.M511763200 (Pubitemid 43848321)
18. Y Cao CY Li BJ Moeller D Yu Y Zhao MR Dreher S Shan MW Dewhirst 2005 Observation of incipient tumor angiogenesis that is independent of hypoxia and hypoxia inducible factor-1 activation Cancer Res 65 5498 5505 10.1158/0008-5472.CAN-04-4553 (Pubitemid 40911147)
19. Y Mizukami J Li X Zhang MA Zimmer O Iliopoulos DC Chung 2004 Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer Cancer Res 64 1765 1772 10.1158/0008-5472. CAN-03-3017 (Pubitemid 38428700)
20. H Tanaka M Yamamoto N Hashimoto M Miyakoshi S Tamakawa M Yoshie Y Tokusashi K Yokoyama Y Yaginuma K Ogawa 2006 Hypoxia-independent overexpression of hypoxia-inducible factor 1alpha as an early change in mouse hepatocarcinogenesis Cancer Res 66 11263 11270 10.1158/0008-5472.CAN-06-1699 (Pubitemid 46009955)
21. S Yasuda S Arii A Mori N Isobe W Yang H Oe A Fujimoto Y Yonenaga H Sakashita M Imamura 2004 Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor 1 alpha and its significance J Hepatol 40 117 123 10.1016/S0168-8278(03)00503-8 (Pubitemid 38064720)
22. M Hojo T Morimoto M Maluccio T Asano K Morimoto M Lagman T Shimbo M Suthanthiran 1999 Cyclosporine induces cancer progression by a cell-autonomous mechanism Nature 397 530 534 10.1038/17401 (Pubitemid 29093252)
23. M Iurlaro A Vacca M Minischetti D Ribatti A Pellegrino A Sardanelli F Giacchetta F Dammacco 1998 Antiangiogenesis by cyclosporine Exp Hematol 26 1215 1222
24. SE Aeder PM Martin JW Soh IM Hussaini 2004 PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways Oncogene 23 9062 9069 10.1038/sj.onc.1208093 (Pubitemid 40013073)
25. L Leseux G Laurent C Laurent M Rigo A Blanc D Olive C Bezombes 2008 PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma Blood 111 285 291 10.1182/blood-2007-04-085092
26. PC Moschella VU Rao PJ [tmp] McDermott D Kuppuswamy 2007 Regulation of mTOR and S6K1 activation by the nPKC isoforms, PKCepsilon and PKCdelta, in adult cardiac muscle cells J Mol Cell Cardiol 43 754 766 10.1016/j.yjmcc.2007.09.015 (Pubitemid 350166390)